HighLife raises €80 million in funding round co-led by Sofinnova Partners, Andera Partners

HighLife, a Paris-based developer of a transcatheter mitral valve replacement system, raised over EUR 80 million in a private financing round co-led by Sofinnova Partners. The funds will support a US pivotal study, European commercial rollout, and organizational growth. The company recently secured a CE mark for its TMVR system and its second-generation Clarity valve.